Youkadi's Innovative IL-6-Silenced CD19 CAR-T Therapy (ssCART-19) Demonstrates High Efficacy and Safety in Relapsed/Refractory B-ALL Including CNS Leukemia at ESMO 2024

From September 13 to 17, 2024, the ESMO 2024 Congress will be officially held in Barcelona, Spain. The European Society for Medical Oncology (ESMO), founded in Europe in 1975, represents more than 35,000 oncology professionals from 172 countries and regions, and is a globally renowned oncology academic organization. As one of the largest, most academically advanced, and authoritative clinical oncology conferences worldwide, numerous experts and scholars will present the latest research achievements in the field of oncology, jointly promoting the global development of oncology.。

This study has a total ofSeventeen subjects received ssCART-19 reinfusion treatment, with an ORR rate as high as 87.5%, including 62.5% CR and 25.0% CRi, and the median OS not reached.

OverallThe incidence of CRS was 76.5%, with no occurrence of grade 4 or higher CRS and any grade of ICANS. More importantly, even subjects with central nervous system infiltration did not experience any grade of ICANS toxic side effects, demonstrating outstanding safety.

Existing clinical research results suggest that,ssCART-19 Product inRefractory and Relapsed Acute Lymphoblastic Leukemia (Including Central Nervous System Leukemia)During treatment, both efficacy and safety have shown excellent performance, with promising prospects.Bring more patientsSurvivalHope and Treatment Options.

About UNICAR-THERAPY

SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD (hereinafter referred to as"UNICAR-THERAPY") is a company dedicated toFrontierBiopharmaceuticals for Cell Therapy Technology Innovation and TranslationLeadingEnterprise, with multiple original core technology platforms, includingSMART Small Nucleotide Gene Regulation Empowerment Technology Platform, MADDS Antibody Innovation Drugability Technology Platform, 6H Production Quality Control Platform, etc.Currently`, Company`AlreadyInNorth Shanghai Biomedical ParkLandedBillion-level Gene and Cell Therapy Research and Industry Center，BuildFinishedInternational first-class immunotherapy tumor innovation technology transformation center and advanced, high-end gene-engineered immune cell industry chain center. UNICAR-THERAPYAlreadyIn China and abroadMultipleWell-knownMedicalInstitutional cooperation has successfully treatedThousandsExample: Advanced Cancer Patients。UNICAR-THERAPY Product PipelineAbundant，Including autologousCAR-T technology, universal CAR-T technology, in vivo CAR technology, indications coverageHematological tumors, solid tumors, and autoimmune diseases.CurrentlyAlreadyThere are threePaymentfirst-in-class/first-in-safeThe product is inRegistered Clinical StudyPhase.ssCART-19 InjectionCanBreakthrough UseContraindications for CAR-T Therapy in the Treatment of Central Nervous System Leukemia (commonly known as "CNS leukemia"),ObtainFDA Orphan Drug Designation, GrantedIncludeNMPAList of Breakthrough Therapies,Has enteredKey Clinical Stage；U16InjectionFor Non-CD19 Target Lymphoma Treatment Product, Significant Efficacy, Soon to Enter Key Clinical Stage; U87InjectionFully HumanCAR-T products, with proposed indications covering various malignant tumors such as lung cancer, triple-negative breast cancer, pancreatic cancer, nasopharyngeal cancer, and colorectal cancer, are currently in Phase I of registrational clinical trials.